IN8bio reports Q3 2022 net loss of $7.4M; updates on INB-100 and INB-400 programs

IN8BIO, INC.

2022-Q3 EPS reported -$1.05

Net loss of $7.4M ($0.34/share) for Q3 2022 vs $3.4M ($0.25) in Q3 2021; R&D expenses rose to $4.3M.
Cash of $27.6M as of Sep 30, 2022, down from $37.0M at Dec 31, 2021; raised $9.8M net from equity offering.
INB-100 Phase 1: all three high-risk AML patients show durable morphologic CR >1 year; two >2 years; no DLTs; ASH data planned.
Filed IND for INB-400; partnered with Univ of Louisville for GMP manufacturing for Phase 2 trial.
Appointed Kenneth LaMontagne as SVP Business Development; added Dr. Michael Bishop to Scientific Advisory Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IN8BIO, INC. reported the third quarter ended September 30, 2022 results: revenue $27.6 million, net income $7.4 million, or $0.34 per basic and diluted common share, EPS $0.34 per basic and diluted common share.

Period: the third quarter ended September 30, 2022
Revenue: $27.6 million
Net income: $7.4 million, or $0.34 per basic and diluted common share
EPS: $0.34 per basic and diluted common share
Result: reported results

Exact text from the filing

of Louisville as the GMP manufacturing center for INB-400. • Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022. NEW YORK, Nov. 10, 2022 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-024177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.